S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$63.33
+0.93 (+1.49 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$62.13
Now: $63.33
$63.59
50-Day Range
$56.65
MA: $59.96
$63.04
52-Week Range
$56.56
Now: $63.33
$85.97
Volume9.36 million shs
Average Volume10.53 million shs
Market Capitalization$79.39 billion
P/E Ratio65.29
Dividend Yield4.29%
Beta0.51
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences logo

MarketRank

Overall MarketRank

2.74 out of 5 stars

Medical Sector

3rd out of 1,556 stocks

Biological Products, Except Diagnostic Industry

1st out of 143 stocks

Analyst Opinion: 4.2Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
CUSIP37555810
Phone650-574-3000
Employees11,800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.45 billion
Cash Flow$7.51 per share
Book Value$17.90 per share

Profitability

Net Income$5.39 billion

Miscellaneous

Outstanding Shares1,253,528,000
Market Cap$79.39 billion
Next Earnings Date2/2/2021 (Estimated)
OptionableOptionable
$63.33
+0.93 (+1.49 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

How has Gilead Sciences' stock price been impacted by COVID-19?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GILD stock has decreased by 14.1% and is now trading at $63.33.
View which stocks have been most impacted by COVID-19
.

Is Gilead Sciences a buy right now?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 2 sell ratings, 15 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Gilead Sciences?

Wall Street analysts have given Gilead Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Gilead Sciences
.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.90 by $0.21. The biopharmaceutical company had revenue of $6.58 billion for the quarter, compared to the consensus estimate of $6.20 billion. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%.
View Gilead Sciences' earnings history
.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Wednesday, October 28th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.68 per share on Wednesday, December 30th. This represents a $2.72 dividend on an annualized basis and a yield of 4.29%. The ex-dividend date is Monday, December 14th.
View Gilead Sciences' dividend history
.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.72 per share and currently has a dividend yield of 4.42%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Gilead Sciences is 44.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.80% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY20 earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of $6.98-7.08 for the period, compared to the Thomson Reuters consensus estimate of $6.60. The company issued revenue guidance of $24.3-24.35 billion, compared to the consensus revenue estimate of $22.54 billion.

What price target have analysts set for GILD?

28 equities research analysts have issued 1-year target prices for Gilead Sciences' stock. Their forecasts range from $61.00 to $625.00. On average, they expect Gilead Sciences' stock price to reach $93.83 in the next year. This suggests a possible upside of 48.2% from the stock's current price.
View analysts' price targets for Gilead Sciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Gilead Sciences?

Gilead Sciences saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 17,670,000 shares, a decline of 14.8% from the December 15th total of 20,730,000 shares. Based on an average daily volume of 9,390,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.4% of the shares of the stock are sold short.
View Gilead Sciences' Short Interest
.

Who are some of Gilead Sciences' key competitors?

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 56, Pay $10.86M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 50, Pay $6.91M)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 52, Pay $2.14M)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 50, Pay $2.55M)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 57, Pay $1.12M)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 58)
  • Ms. Jyoti K. Mehra, Exec. VP of HR
  • Dr. William A. Lee, Exec. VP of Research (Age 65)
  • Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 66)
  • Dr. Diana Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 49)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.05%), Nexus Investment Management ULC (0.02%), Gofen & Glossberg LLC IL (0.02%), RNC Capital Management LLC (0.02%), Crossmark Global Holdings Inc. (0.01%) and Cardinal Capital Management Inc. (0.01%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences
.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, RNC Capital Management LLC, Thomasville National Bank, Lawson Kroeker Investment Management Inc. NE, North Star Investment Management Corp., NuWave Investment Management LLC, First Citizens Bank & Trust Co., and First American Bank. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, and Olsen Per Wold.
View insider buying and selling activity for Gilead Sciences
or view top insider-selling stocks.

Which major investors are buying Gilead Sciences stock?

GILD stock was bought by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Hohimer Wealth Management LLC, Hohimer Wealth Management LLC, IFM Investors Pty Ltd, Westside Investment Management Inc., Cardinal Capital Management Inc., Fulton Bank N.A., and OneAscent Financial Services LLC.
View insider buying and selling activity for Gilead Sciences
or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $63.33.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $79.39 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.